Skip to main content
SpringerLink
Log in
Book cover

Combined Modality Therapy of Gastrointestinal Tract Cancer pp 36–43Cite as

Phase-III Clinical Trial of Adjuvant FAM2 (5-FU, Adriamycin and Mitomycin C) vs Control in Resectable Gastric Cancer: A Study of the EORTC Gastrointestinal Tract Cancer Cooperative Group

  • Conference paper

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 110))

Abstract

Despite a reported decrease in incidence, gastric carcinoma remains a major oncologic problem in Western Europe. Surgery is at present the only hope for cure. The 5-year survival after curative surgery is about 40% for stage 2 and 20% for stage 3.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. MacDonald JS, Schein PS, Wooley PV, et al. (1980) 5-Fluorouracil, doxorubicin, mitomycin C (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533

    PubMed  CAS  Google Scholar 

  2. Bitran JD, Desser RK, Kozzloff MF, et al. (1979) Treatment of metastatic pancreatic and gastric adenocarcinoma with fluorouracil, adriamycin and mitomycin C (FAM). Cancer Treat Rep 36: 2049

    Google Scholar 

  3. Panettiere PJ, Heiburn L (1981) Experience with two treatment schedules in combination chemotherapy of advanced gastric carcinoma. In: Carter S, Crooke S (eds) Mitomycin C: current status and new developments. Flam Academic, Orlando, pp 145–157

    Google Scholar 

  4. Fornasiero A, Cartei G, Daniele O, Fosser V, Fiorentino M (1982) FAM2 regimens in disseminated gastric cancer. Eur Soc Med Onc 8: 74

    Google Scholar 

  5. Cartei G, Fornasiero A, Daniele O, Favretti F, Nitti D, Lise M, Fiorentino M (1982) Adjuvant FAM after radical surgery in gastric carcinoma. Abstract, 1st Eur Soc Surg Oncol, p 101

    Google Scholar 

  6. The Gastrointestinal Tumor Study Group (1982) Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49: 1116

    Article  Google Scholar 

  7. Higgins GA, Amadeo JH, Smith DE, et al. (1983) Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology Group report. Cancer 52: 1105

    Article  PubMed  CAS  Google Scholar 

  8. Engstrom PF, Lavin PT, Douglass HO jr, et al. (1985) Postoperative adjuvant 5-fluoro-uracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group Study (EST 3275). Cancer 55: 1868

    Article  PubMed  CAS  Google Scholar 

  9. Fielding JWL, Fagg SL, Jones BG, et al. (1983) An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer. British Stomach Cancer Group. World J Surg 7: 390

    Article  PubMed  CAS  Google Scholar 

  10. Schlag P, Schreml W, Gaus W, et al. (1982) Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results. In: Mathé G, Bonadonna G, Salmon S (eds) Adjuvant therapies of cancer. Recent results in cancer research, vol. 80. Springer-Verlag, Berlin Heidelberg New York, p 277

    Google Scholar 

  11. Inokuchi K, Hattori T, Taguchi T, et al. (1984) Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years. Cancer 53: 2393

    Article  PubMed  CAS  Google Scholar 

  12. Akiyoshi T, Kawaguchi M, Arinaga S, et al. (1984) A trial of adjuvant combination chemoimmunotherapy for stage-III carcinoma of the stomach. J Surg Oncol 26: 86

    Article  PubMed  CAS  Google Scholar 

  13. Douglass HO jr (1985) Gastric cancer: overview of current therapies. Semin Oncol 12: 57

    PubMed  Google Scholar 

  14. Cullinan SA, Moertel CG, Fleming TR, et al. (1985) A comparison of three chemother-apeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluo-rouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253: 2061

    Article  PubMed  CAS  Google Scholar 

  15. Schein PS, Coombes RC, Chilvers C (1986) A controlled trial of FAM (5-FU — doxoru-bucin — mitomycin) chemotherapy as adjuvant treatment for resected gastric carcinoma: an interim report. Proc American Society of Clinical Oncology, no 308

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Patologia Chirurgia 1a, Universita degli Studi di Padova, Via Giustiniani 2, 35100, Padova, Italy

    M. Lise, D. Nitti, M. Buyse, G. Cartei, A. Fornasiero, J. Guimaraes dos Santos & N. Duez

Authors
  1. M. Lise
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Nitti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Buyse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Cartei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Fornasiero
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Guimaraes dos Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Duez
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Chirurgische Klinik, Klinikum der Universität Heidelberg, Im Neuenheimer Feld 110, 6900, Heidelberg, Germany

    Peter Schlag  & Peter Hohenberger  & 

  2. Departement Chirurgie, Universitätsspital Zürich, Rämistraße 100, 8091, Zürich, Switzerland

    Urs Metzger

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Lise, M. et al. (1988). Phase-III Clinical Trial of Adjuvant FAM2 (5-FU, Adriamycin and Mitomycin C) vs Control in Resectable Gastric Cancer: A Study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. In: Schlag, P., Hohenberger, P., Metzger, U. (eds) Combined Modality Therapy of Gastrointestinal Tract Cancer. Recent Results in Cancer Research, vol 110. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83293-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83293-2_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-83295-6

  • Online ISBN: 978-3-642-83293-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation